- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Monheim, December 7, 2017 – Bayer today launched its new transparency website (https://cropscience-transparency.bayer.com), designed to enable access to scientific data needed for the evaluation of plant protection products. With this step, Bayer is taking a leadership role in driving transparency, while safeguarding the company’s confidential product composition and manufacturing process data.
In addition to summaries of safety-related study reports for a significant number of active substances, Bayer will start to enable non-commercial access to the respective safety-related study reports, commencing with reports on imidacloprid. Background material such as videos and infographics are provided to help put regulatory science into context. In this way, Bayer wants to foster an open and transparent dialog.
“As conflicting accounts about the safety of food or technologies are making it difficult for people to separate fact from fiction, this Bayer initiative is an important step towards increased transparency,” said Dr. Adrian Percy, global head of Research and Development for the Crop Science Division. “By sharing safety data, which was previously only shared with authorities, we hope to connect the public with our scientific community in a way that builds trust and shows our desire to further create transparency.”
“We are excited to launch our new website which also aims to support authorities around the globe by providing an alternative tool, other than filing freedom of information requests, for them to obtain the documents which underlie our registration procedures,” said Percy. “We want non-commercial interested parties – from a concerned citizen to a member of the scientific community – to be able to access safety-relevant information in a way that is quick and easy to understand, so that they can base their opinions on scientific data.”
Bayer's new transparency website will be updated on a regular basis. In the next phase, which is planned for early 2018, non-commercial users will be able to request access to additional full, in-depth safety-related study reports. Furthermore, Bayer plans to add other language options to its new website, for example German.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 99,600 people and had sales of EUR 34.9 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.